2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 260-262
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Bispecific Antibody Therapy, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Study Population, Human
PAPER

105 Epcoritamab plus venetoclax leads to high response rates in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): First results from dose cohorts 1 and 2 of the EPCORE CLL-1 trial

Alexey V. Danilov, MD, PhD, Martin Simkovic, MD2, Seema Ali Bhat, MD3, Wojciech Jurczak, MD, PhD4, Bita Fakhri, MD, MPH5, Christian Bjørn Poulsen, MD6, Clare Sun, MD7, Adrian Wiestner, MD, PhD8, Philip Thompson, MB, BS9, Orlando Bueno, MD, PhD10, Andrew J Steele, PhD11, Marie Holst Mørch, MSc12, Ernestine Tucker, MSc13, Ramin Tehranchi, MD, PhD14, Farrukh T Awan, M.D.M.S.,M.B.A.15
1 City of Hope, Duarte, California, United States
2 4th Department of Internal Medicine – Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
3 Division of Hematology, The Ohio State University, Columbus, Ohio, United States
4 Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland
5 Stanford Cancer Institute, Stanford University, Palo Alto, California, United States
6 Zealand University Hospital, Roskilde, Denmark
7 National Heart, Lung, and Blood Institute, National Institutes of Health (at the time of analysis), Bethesda, Maryland, United States
8 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
9 Department of Clinical Haematology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, Department of Clinical Oncology, The Sir Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Victoria, Australia
10 AbbVie, North Chicago, Illinois, United States
11 Genmab, Plainsboro, New Jersey, United States
12 Genmab, Copenhagen, Denmark
13 Genmab, Plainsboro, New Jersey, United States
14 Genmab, Plainsboro, New Jersey, United States
15 University of Texas Southwestern Medical Center, Dallas, Texas, United States

Introduction: Around 80% of patients with R/R CLL respond to treatment with BTK and BCL2 inhibitors (BTKi and BCL2i), but most will experience disease progression and have limited therapeutic options. Epcoritamab (epcor), a subcutaneous CD3xCD20 bispecific antibody, has shown encouraging efficacy and safety as monotherapy in R/R CLL. Preclinical studies have shown that venetoclax (ven), a BCL2i approved for CLL treatment, potentiates epcor activity. We present the first clinical and translational results from the dose escalation cohorts of the phase 1b/2 EPCORE® CLL-1 trial (NCT04623541), evaluating epcor + ven in patients with R/R CLL.

Methods: Eligible patients had R/R CLL requiring treatment per iwCLL 2018 criteria, received ≥1 prior LOT (pLOT) with a systemic antineoplastic agent, and did not receive prior ven within 24 mo of ramp-up dosing. Ven was administered daily during a 5-week ramp-up period before Cycle (C)1, then 400 mg daily in C1–C26. Patients received fixed-duration epcor in 24 mg (Cohort 1) or 48 mg (Cohort 2) doses in 28-day (D) cycles: QW in C1–3, Q2W in C4–9, and Q4W in C10–C26, with 3 step-up doses in C1 (0.16 mg, 0.8 mg, and 3 mg) prior to the first full dose. The primary endpoints were the incidence of dose-limiting toxicities (DLTs) and incidence and severity of TEAEs. Secondary endpoints included ORR, CR rate, PFS, OS, and undetectable MRD (uMRD; assessed by clonoSEQ [Adaptive Biotechnologies] in peripheral blood with sensitivities of 10-4 and 10-5). Results were pooled across cohorts.

Results: As of Mar 21, 2026, 40 patients received epcor + ven (Cohort 1: n=20; Cohort 2: n=20). Baseline characteristics were similar between cohorts: median age was 66 y, patients received a median of 2 pLOTs (range: 1–9), 98% had an ECOG PS of 0–1, 65% had unmutated IGHV, 25% had TP53 mutations, and 18% had del(17p) alterations. All patients received prior treatment with targeted agents: 80% received a BTKi (75% received a covalent BTKi; 18% received a non-covalent BTKi) with 55% being refractory, and 33% received a BCL2i.

Median follow-up for all patients was 16.4 mo (95% CI, 6.8–18.6). No DLTs were observed. All patients had a TEAE; 78% had grade ≥3 TEAEs and 63% had serious TEAEs. TEAEs led to treatment discontinuation in 15% of patients and dose delay/interruption in 70%. There was 1 fatal TEAE (diarrhea, unrelated to trial drug). The most common TEAEs were neutrophil count decreased (43% [17/40]; no febrile neutropenia was observed), diarrhea (40% [16/40]), and CRS (40% [16/40]). CRS rates were similar between cohorts; all events were low grade (grade 1, 25% [10/40]; grade 2, 15% [6/40]) and resolved within a median of 2 days. Infections occurred in 75% of patients (30/40), with upper respiratory tract infections most common (38% [15/40]). Most infections were grade 1–2 (60% [24/40]; grade 3, 15% [6/40]); there were no grade 4–5 infections. Intravenous immunoglobulin was administered in 28% (11/40) of patients. No patient had ICANS or clinical or laboratory TLS.

ORR in the pooled population was 83% (95% CI, 67–93) and CR rate was 25% (95% CI, 13–41); no patient had PD. Median DOR, PFS, and OS were not reached. The estimated 12-mo PFS, OS, and DOR rates were all 94%, with data still maturing. Among biomarker-evaluable responders (n=22), uMRD4 (cutoff:10-4) was achieved by C3D1 in 91%, with 1 additional patient achieving uMRD4 by C10; results were similar with a 10-5 cutoff (uMRD5; 86%). Rates of uMRD4 and uMRD5 were sustained through C13.

B cells (including CLL and healthy B cells) were depleted prior to the first full dose of epcor on C1D22. Ven led to a median reduction in circulating CD4 and CD8 T-cell counts of 60% and 48%, respectively, during ramp-up prior to epcor treatment, and T-cell counts recovered towards healthy normal levels (>700 cells/µL) by C3D1.

Conclusions: The safety profile of epcor + ven in R/R CLL was consistent with the known profiles of each compound and high response rates were observed. Infections were mostly low grade, with no additional safety signals. The incidence and severity of CRS were reduced after debulking with ven compared to prior reports of epcor monotherapy in EPCORE CLL-1. Early and sustained uMRD4 and uMRD5 were achieved in this high-risk R/R CLL population whose disease was enriched for TP53 aberrations and prior BTKi exposure. The encouraging safety and efficacy findings highlight the potential of epcor-based combination strategies to improve outcomes in R/R CLL.

Alexey V. Danilov, MD, PhD: Regeneron - Research Funding; GenMab - Research Funding; Nurix Therapeutics - Research Funding; Prelude - Research Funding; BeOne Medicines - Research Funding; Lilly Oncology - Research Funding; Merck - Research Funding; Incyte - Research Funding; Regeneron - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Lilly Oncology - Consultancy (Includes expert testimony); GenMab - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)